Personalized exosome Potential sales opportunity in providing personalized exosome-based drug delivery solutions (EXOKIT) tailored to individual patient therapies, offering reduced dosages and minimized side effects to attract pharmaceutical partners seeking precision medicine capabilities.

Collaborative validation Leverage the collaboration with Harvard Medical School and MIT’s Biomedical Engineering Center to position joint development programs as a credibility boost when approaching academic partnerships, biotechs, or large pharma customers seeking proven innovation.

Exosome library Capitalize on HTS-ExoPlatform capabilities and the natural exosome library with extensive small RNA and DNA sequences to offer unique discovery services, potential licensing, or collaboration on novel biomarker and therapeutic target programs.

Downstream efficiency Highlight cost-effective, high-throughput platforms to prospective customers focused on rapid screening and scalable workflows, appealing to research partners and CROs aiming to accelerate drug discovery timelines.

Early-stage traction Revenue is under one million; this signals an opportunity to target biotech startups and mid-stage companies seeking nimble, innovative exosome technology at approachable entry points, with potential for strategic partnerships and co-development deals.